MedPath

Octreotide

Generic Name
Octreotide
Brand Names
Bynfezia, Mycapssa, Sandostatin
Drug Type
Biotech
CAS Number
83150-76-9
Unique Ingredient Identifier
RWM8CCW8GP
Background

Acromegaly is a disorder caused by excess growth hormone (GH), increasing the growth of body tissues and causing metabolic dysfunction. In most cases, it results from an anterior pituitary growth hormone-releasing tumor. Typically, the feet, hands, and face grow abnormally large; organomegaly and insulin resistance may also occur. Acromegaly is a life-threatening disease requiring life-long management.

Octreotide is a long-acting drug with pharmacologic activities that mimic those of the natural hormone, somatostatin, which inhibits the secretion of growth hormone. Additionally, it is used for the treatment of acromegaly and symptoms arising from various tumors, including carcinoid tumors and vasoactive intestinal tumors (VIPomas). In the past, octreotide has been administered solely by injection. On June 26, 2020, the first approved delayed-release oral somatostatin analog, Mycapssa, received FDA approval for the long term maintenance treatment of acromegaly. This drug was developed by Chiasma Inc.

Indication

Octreotide by injection is used for the treatment of acromegaly and the reduction of flushing and diarrhea symptoms related to carcinoid tumors and/or vasoactive intestinal peptide (VIPoma) tumors. The delayed-release oral formulation is used for the long-term treatment of acromegaly in patients who tolerate and respond adequately to injectable octreotide and lanreotide.

Associated Conditions
Acromegaly, Diarrhea, Metastatic Carcinoid Tumors
Associated Therapies
Long-term maintenance therapy
Clinical Trials
Related News

CDMO Market Report: Key Regulatory Approvals and Clinical Advances in March-April 2025

• Multiple CDMOs secured significant contract manufacturing opportunities as regulatory bodies approved new indications for established drugs, particularly in oncology and rare diseases. • AstraZeneca's portfolio saw substantial growth with expanded approvals for Imfinzi, Tagrisso, and Lynparza, strengthening partnerships with contract manufacturers including Lonza, Dottikon, and Samsung Biologics. • Contract manufacturers supporting treatments for autoimmune conditions showed strong performance, with Argenx's Vyvgart Hytrulo receiving expanded indications for myasthenia gravis and CIDP.

Phase 3 Clinical Trials Showcase Growing Promise of Radiopharmaceutical Cancer Therapy

• Radiopharmaceutical therapy has emerged as a breakthrough treatment modality, combining targeted molecular delivery with radionuclide properties for precise cancer treatment. • Recent successful Phase 3 trials have provided crucial clinical evidence, marking a significant shift in establishing radiopharmaceutical therapy in treatment protocols. • Multiple active Phase 3 clinical trials are currently exploring radiopharmaceutical applications across various cancer types, demonstrating the field's rapid expansion.

FDA Issues Complete Response Letter for Camurus' CAM2029 in Acromegaly

• The FDA issued a Complete Response Letter (CRL) for Camurus' CAM2029 (octreotide) extended-release injection for acromegaly due to manufacturing deficiencies. • The CRL is linked to a third-party manufacturer's cGMP inspection in September 2024, with no concerns about CAM2029's clinical efficacy or safety. • Camurus is collaborating with the FDA and the manufacturer to address the issues and expedite the drug's availability for acromegaly patients. • A Market Authorization Application for CAM2029 is under review in the EU, and development programs for other indications are ongoing.

FDA Wraps Up 2024 with Key Approvals for Drugs Targeting Various Conditions

• The FDA approved Vertex's Alyftrek for cystic fibrosis, offering improved dosing and potential market exclusivity. • Novo Nordisk's Alhemo was approved for hemophilia A and B, providing a new option for patients with inhibitors. • Bristol Myers Squibb's Opdivo Qvantig gained approval as a subcutaneous formulation, offering faster administration for various solid tumors. • Eli Lilly's Zepbound secured approval for obstructive sleep apnea in obese adults, marking the first prescription medicine for this condition.

FDA's Manufacturing Concerns Delay Access to Promising Drugs

• The FDA has recently rejected drugs for acromegaly and gastric cancer due to manufacturing facility deficiencies, despite evidence of their safety and efficacy. • This risk-averse approach delays patient access to potentially life-improving medications, such as CAM2029 for acromegaly and zolbetuximab for gastric cancer. • Experts suggest the FDA should prioritize recalls for faulty batches over rejecting entire medications, especially when drugs meet safety and efficacy standards. • Calls are growing for legislative reform to prevent manufacturing issues from being the sole basis for drug rejections, advocating for a more flexible approach.

NETTER-2 Trial: 177Lu-Dotatate Shows Promise but Raises Questions in High-Grade NETs

• The NETTER-2 trial demonstrated that 177Lu-dotatate significantly prolonged progression-free survival in patients with high-grade gastroenteropancreatic neuroendocrine tumors. • Response rates were notably higher in the 177Lu-dotatate group compared to the control group, indicating a potential for improved disease control. • Quality of life measurements showed no significant difference between the treatment arms, raising concerns about the overall benefit of first-line 177Lu-dotatate. • Hematologic toxicities and the risk of myelodysplastic syndrome warrant careful consideration when selecting patients for 177Lu-dotatate therapy.

FDA Accepts Alvotech and Teva's Biosimilar Application for Golimumab (AVT05)

• The FDA has accepted the BLA for AVT05, a biosimilar to Simponi/Simponi Aria (golimumab), marking the first such acceptance in the U.S. • AVT05 is intended for inflammatory conditions like rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and ulcerative colitis. • The FDA's decision on AVT05 is expected in Q4 2025, potentially offering a cost-saving alternative for patients. • Clinical studies have demonstrated comparable efficacy, safety, and immunogenicity between AVT05 and the reference golimumab.

FDA Issues Complete Response Letter for Camurus' Acromegaly Drug CAM2029

• The FDA issued a Complete Response Letter (CRL) for Camurus' CAM2029, an extended-release octreotide injection, intended for treating acromegaly, citing manufacturing deficiencies. • The CRL was prompted by issues identified during a Current Good Manufacturing Practices (cGMP) inspection at a third-party manufacturing facility. • Camurus is collaborating with the FDA and the third-party manufacturer to address the identified deficiencies and resolve the issues for CAM2029 approval. • CAM2029's European Union market authorization application remains under review, and its development for other indications is ongoing, unaffected by the FDA's decision.

FDA Grants Orphan Drug Status to Immuneering's IMM-1-104 for Pancreatic Cancer

• Immuneering's IMM-1-104 receives Orphan Drug Designation from the FDA for pancreatic cancer treatment, offering potential tax credits and marketing exclusivity. • Phase 2a trial data showed complete and partial responses in first-line pancreatic cancer patients when IMM-1-104 was combined with chemotherapy. • The FDA had previously granted Fast Track designation to IMM-1-104 for both first and second-line pancreatic cancer treatments earlier this year. • Immuneering anticipates releasing initial data from an additional arm of the Phase 2a trial by the end of the year, further evaluating IMM-1-104.

FDA Gears Up for October: Key Decisions on Novel Therapies Expected

• Biofrontera's Ameluz seeks expanded dosage approval for actinic keratosis treatment, potentially improving convenience for patients and dermatologists. • Bristol Myers Squibb awaits FDA decision on Opdivo for perioperative treatment of resectable stage IIA to IIIB non-small cell lung cancer. • Camurus' Oclaiz, a long-acting Octreotide formulation, is under review for acromegaly, offering potential self-administration and higher bioavailability. • Lexicon Pharmaceuticals' Zynquista faces FDA panel discussion for type 1 diabetes with chronic kidney disease, marking its second review attempt.

FDA Gears Up for Key Approval Decisions in Q4 2024

• The FDA is set to decide on dasiglucagon for congenital hyperinsulinism, with a PDUFA date of October 8, potentially benefiting pediatric patients. • Nivolumab-based regimens for resectable NSCLC are under review, supported by Phase 3 data showing a 42% reduction in disease recurrence, with a PDUFA date of October 8. • Acoramidis for transthyretin amyloid cardiomyopathy shows promise, with Phase 3 results indicating statistically significant improvements and a PDUFA date of November 29. • Zanidatamab for HER2-amplified biliary tract cancer is under review, supported by Phase 2b data showing a 41.3% objective response rate, with a PDUFA date of November 29.

FDA Accepts Camurus' NDA for Oclaiz™ (CAM2029) in Acromegaly Treatment

• The FDA has accepted Camurus' New Drug Application (NDA) for Oclaiz™ (CAM2029) for treating acromegaly, setting a PDUFA target action date of October 21, 2024. • Oclaiz™ is a novel, once-monthly subcutaneous depot formulation of octreotide designed for convenient self-administration and enhanced drug exposure. • The NDA is supported by data from seven clinical studies, including two Phase 3 trials within the ACROINNOVA program, demonstrating superior biochemical control compared to placebo. • Camurus aims to provide an effective treatment option for acromegaly patients, potentially reducing treatment burden and improving their quality of life.
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy